 |
PDBsum entry 2wu3
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Crystal structures of oxime-Bound fenamiphos-Acetylcholinesterases: reactivation involving flipping of the his447 ring to form a reactive glu334-His447-Oxime triad.
|
 |
|
Authors
|
 |
A.Hörnberg,
E.Artursson,
R.Wärme,
Y.P.Pang,
F.Ekström.
|
 |
|
Ref.
|
 |
Biochem Pharmacol, 2010,
79,
507-515.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Organophosphorus insecticides and nerve agents inhibit the vital enzyme
acetylcholinesterase by covalently bonding to the catalytic serine residue of
the enzyme. Oxime-based reactivators, such as
[(E)-[1-[(4-carbamoylpyridin-1-ium-1-yl)methoxymethyl]pyridin-2-ylidene]methyl]-oxoazanium
dichloride (HI-6) and 1,7-heptylene-bis-N,N'-2-pyridiniumaldoxime dichloride
(Ortho-7), restore the organophosphate-inhibited enzymatic activity by cleaving
the phosphorous conjugate. In this article, we report the intermolecular
interactions between Mus musculus acetylcholinesterase inhibited by the
insecticide fenamiphos (fep-mAChE) and HI-6 or Ortho-7 revealed by a combination
of crystallography and kinetics. The crystal structures of the two oxime-bound
fep-mAChE complexes show that both oximes interact with the peripheral anionic
site involving different conformations of Trp286 and different peripheral-site
residues (Tyr124 for HI-6 and Tyr72 for Ortho-7). Moreover, residues at
catalytic site of the HI-6-bound fep-mAChE complex adopt conformations that are
similar to those in the apo mAChE, whereas significant conformational changes
are observed for the corresponding residues in the Ortho-7-bound fep-mAChE
complex. Interestingly, flipping of the His447 imidazole ring allows the
formation of a hydrogen bonding network among the Glu334-His447-Ortho-7 triad,
which presumably deprotonates the Ortho-7 oxime hydroxyl group, increases the
nucleophilicity of the oxime group, and leads to cleavage of the phosphorous
conjugate. These results offer insights into a detailed reactivation mechanism
for the oximes and development of improved reactivators.
|
 |
|
|
|
|
 |